Cingulate: This Novel Drug Technology May Soon Relieve A Patient's "Pill-Burden"

Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), was recently a guest on Benzinga’s All-Access.

Cingulate is a clinical-stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety associated disorders.

The company has a patented technology dubbed PTR that underpins three drug candidates currently advancing through the development pipeline - CTx1301, CTx1302, and CTx1303.

Watch the full interview here:

Featured photo by Christina Victoria Craft on Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.